Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Fulcrum Therapeutics to post earnings of ($0.28) per share for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.
Fulcrum Therapeutics Stock Up 0.1 %
FULC stock traded up $0.01 on Friday, reaching $3.86. 283,505 shares of the company's stock were exchanged, compared to its average volume of 460,906. The stock has a fifty day moving average of $4.18 and a 200-day moving average of $4.75. The firm has a market cap of $207.94 million, a PE ratio of -12.44 and a beta of 2.03. Fulcrum Therapeutics has a twelve month low of $2.86 and a twelve month high of $13.70.
Wall Street Analyst Weigh In
FULC has been the topic of several research analyst reports. Royal Bank of Canada reissued a "sector perform" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. HC Wainwright reiterated a "neutral" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $9.33.
Read Our Latest Analysis on FULC
About Fulcrum Therapeutics
(
Get Free Report)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
Further Reading
Before you consider Fulcrum Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulcrum Therapeutics wasn't on the list.
While Fulcrum Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
